GlassScriptPhysician profile
John J Santoro
NPI 1245308196
$80,493.40
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $16K.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42,152.81 | 2019-2020 | |
| Gilead Sciences, INC. | $20,921.93 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $9,914.60 | 2019 | |
| Intercept Pharmaceuticals, INC. | $5,132.19 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $484.55 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $423.53 | 2019-2020 | |
| Janssen Biotech, INC. | $242.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $221.19 | 2019-2020 | |
| Qol Medical, LLC | $218.52 | 2019-2020 | |
| Pfizer INC. | $155.86 | 2019-2020 | |
| Allergan, INC. | $147.99 | 2019-2020 | |
| Shionogi INC | $109.00 | 2019-2020 | |
| Daiichi Sankyo INC. | $94.55 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $62.89 | 2019 | |
| Ucb, INC. | $52.35 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $43.79 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $35.98 | 2019 | |
| Dova Pharmaceuticals | $28.25 | 2019 | |
| Ironwood Pharmaceuticals, INC | $27.18 | 2020 | |
| Horizon Therapeutics Plc | $12.57 | 2019 | |
| Boston Scientific Corporation | $10.91 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$363.48 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Santoro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.